The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market.
Gilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) combining compounds from each of their pipelines, including Novo
Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.
Novo Nordisk and devices firm Abbott have announced a partnership that aims to make diabetes management easier by linking technologies such as continuous glucose monitoring with connected i
The US regulator has approved Novo Nordisk’s long-acting therapy for haemophilia A, Esperoct, as the Danish pharma seeks to maintain its presence in an increasingly competitive sector of th
Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.